Hubungan Parameter Koagulasi dengan Tipe, Ukuran, dan Jumlah Perdarahan pada Operasi Tumor Otak Supratentorial

Endy Sugiyanto, Dewi Yulianti Bisri

Abstract


Latar Belakang dan Tujuan: Tumor otak memiliki angka kejadian 3,8-5,5% dari semua kasus tumor di Indonesia. Kebanyakan kasus tumor otak mengalami hiperkoagulasi, meskipun terdapat pengecualian pada beberapa kasus. Tujuan penelitian untuk mengetahui hubungan koagulopati dengan tipe, ukuran, dan jumlah perdarahan pada operasi tumor otak supratentorial
Subyek dan Metode: Penelitian observasional analitik pada 30 pasien dengan rancangan cross-sectional pengukuran berulang untuk menganalisis hubungan antara koagulopati dengan tipe, ukuran, dan perdarahan tumor otak. Pengambilan sampel penelitian dilakukan secara consecutive sampling
Hasil: Terdapat 17 orang pasien dengan meningioma, 2 orang pasien dengan oligodendroglioma, 3 orang pasien dengan metastase dan 8 orang dengan tumor lain. Rata-rata bleeding time, clotting time, protrombin time (PT), dan activated partial thromboplastin time (APTT) preoperatif, 2 jam dan 6 jam post operatif berada dalam rentang nilai normal. Ditemukan penurunan yang konstan pada data APTT. Terdapat hubungan negatif yang signifikan antara ukuran tumor dengan bleeding time preoperatif serta hubungan yang signifikan antara jumlah pendarahan dengan APTT preoperatif.
Simpulan: Pasien tumor otak mungkin mengalami kondisi hiperkoagulasi dari hasil pemeriksaan faktor koagulasi sederhana, terdapat hubungan negatif antara ukuran tumor dan bleeding time sehingga semakin besar ukuran tumor semakin besar juga risiko hiperkoagulasi yang mungkin dialami pasien.

 

Correlation between Coagulation Parameter and Type, Size, and Blood Loss in Supratentorial Brain Tumor Surgery

Abstract

Background and Objective: The incidence rate of brain tumor 3.8-5.5% of all tumor cases in Indonesia. Most of brain tumor patients experience hypercoagulation, although there are exception in some cases. The purpose of this study to know the relationship between coagulopathy and brain tumor supratentorial type, size, and number of bleeding on operation.
Subject and Methods: This is an observational analytical cross-sectional design for 30 patient to analyze correlation between coagulopathy and brain tumor type, size, and bleeding. The sampling methods were consecutive sampling
Result: There were 17 patients with meningioma, 2 patients with oligodendroglioma, 3 patients with metastasis and 8 patients with other type of tumor. The average of bleeding time, clotting time, protrombin time (PT), dan activated partial thromboplastin time (APTT) in preoperative, 2 hours and 6 hours were normal. There were constant decline of APTT. Negative correlation between tumor size and preoperative bleeding time and significant correlation between amount of bleeding and preoperative APTT were also found.
Conclusion: From simple coagulation factor test result, it is very like for a brain tumor patient to experience hypercoagulative state, a negative correlation between tumor size and bleeding time, meaning the bigger the tumor size, the higer hypercoagulation risk possesed by the patient.


Keywords


Tumor Otak; Koagulopati; Hemostasis; Ukuran; Jenis; Perdarahan; Brain tumor; coagulopathy; hemostasis; size; type; bleeding

Full Text:

PDF

References


Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, dkk. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro-oncology. 2013;15(suppl 2):ii1-ii56.

Oemiati R, Rahajeng E, Kristanto AY. Prevalensi tumor dan beberapa faktor yang mempengaruhinya di Indonesia. Buletin Penelitian Kesehatan. 2011;39(4 Des):190–204.

Kanker KNP. Panduan Nasional Penanganan Kanker: Tumor Otak. Edisi. Jakarta: Kementerian Kesehatan Republik Indonesia; 2015.

Cote DJ, Smith TR. Venous thromboembolism in brain tumor patients. Journal of Clinical Neuroscience. 2016;25:13-8.

D’Asti E, Fang Y, Rak J. Brain neoplasms and coagulatio-lessons from heterogeneity. Rambam Maimonides Medical Journal. 2014;5(4).

Perry JR. Thromboembolic disease in patients with high-grade glioma. Neuro-oncology. 2012;14(suppl_4):iv73-iv80.

Sierko E, Wojtukiewicz MZ, Kisiel W, editors. The role of tissue factor pathway inhibitor-2 in cancer biology. Seminars in thrombosis and hemostasis; 2007: © Thieme Medical Publishers.

Zhu J-F, Cai L, Zhang X-W, Wen Y-S, Su X-D, Rong T-H, dkk. High plasma fibrinogen concentration and platelet count unfavorably impact survival in non–small cell lung cancer patients with brain metastases. Chinese journal of cancer. 2014;33(2):96.

Kvolik S, Jukic M, Matijevic M, Marjanovic K, Glavas-Obrovac L. An overview of coagulation disorders in cancer patients. Surgical oncology. 2010;19(1):e33–e46.

Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects. Journal of Thrombosis and Haemostasis. 2013;11(2):223–33.

Goh KY-C, Tsoi W-C, Feng C-S, Wickham N, Poon WS. Haemostatic changes during surgery for primary brain tumours. Journal of Neurology, Neurosurgery & Psychiatry. 1997;63(3):334–8.

Goobie SM, Soriano SG, Zurakowski D, McGowan FX, Rockoff MA. Hemostatic changes in pediatric neurosurgical patients as evaluated by thrombelastograph®. Anesth Analg. 2001;93(4):887–92.

Suega K, Bakta IM. Correlation between clinical stage of solid tumor and D dimer as a marker of coagulation activation. Acta Med Indones. 2011;43(3):162–7.

Sivanaser V, Manninen P. Preoperative assessment of adult patients for intracranial surgery. Anesthesiology research and practice. 2010;2010.

Sun NC, McAfee WM, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients: Part I. Coagulation studies. American Journal of Clinical Pathology. 1979;71(1):10–6.

Jo JT, Schiff D, Perry JR, editors. Thrombosis in brain tumors. Seminars in thrombosis and hemostasis; 2014: Thieme Medical Publishers.




DOI: https://doi.org/10.24244/jni.v8i2.201

Refbacks

  • There are currently no refbacks.


                                    

 

JNI is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License